Alife Health, a San Francisco, CA-based fertility technology company building artificial intelligence tools to advance in-vitro fertilization (IVF), announced it raised $22 million in Series A financing.
The round was co-led by existing Seed lead Deena Shakir at Lux Capital, and new investors Rebecca Kaden at Union Square Ventures and Anarghya Vardhana at Maveron, both of whom will also be joining Alife's Board of Directors.
With its new funding, Alife plans to bring its first two products to market and continue conducting clinical studies for a third product.
Company: Alife Health
Round: Series A
Funding Month: March 2022
Lead Investors: Lux Capital, Union Square Ventures and Maveron
Company Website: https://www.alifehealth.com/
Software Category: AI-powered Fertility Care
About the Company: Founded by Paxton Maeder-York in 2020, Alife's mission is to modernize and personalize the IVF process with cutting-edge artificial intelligence technology to improve outcomes and care for all. The company has built a consortium of partnerships with the top clinics and most renowned physicians to bring significant clinical improvements to patients globally. With Alife's mobile app, patients will gain a comprehensive platform that includes educational resources and easy-to-use organizational tools for medication reminders, appointments, lab results, and more. Today, the 180 million people around the world who struggle with infertility face treatment options that are both expensive and inaccessible. The average IVF cycle can cost up to $25,000 in the U.S., and patients typically go through 3 to 5 cycles to have a baby.